modelD01BA01
Extends from Pharmacokinetic.Models.PK_1C_enteral.
Information
| name: | Griseofulvin | |
| ATC code: | D01BA01 | route: | oral |
| compartments: | 1 | |
| dosage: | 500 | mg |
| volume of distribution: | 0.7 | L |
| clearance: | 0.45 | L/h/kg |
| other parameters in model implementation | ||
Griseofulvin is an antifungal medication primarily used to treat dermatophytic infections (skin, hair, nails) caused by Trichophyton, Microsporum, and Epidermophyton species. It inhibits fungal cell mitosis by interfering with microtubule function. Griseofulvin is approved and used in human medicine, although its use has declined due to newer antifungal agents.
Pharmacokinetics
Pharmacokinetic parameters were reported in healthy adult volunteers after oral administration of griseofulvin micronized tablets.
References
Gupta, AK, et al., & Cooper, EA (2003). The efficacy and safety of terbinafine in children. Journal of the European Academy of Dermatology and Venereology : JEADV 17(6) 627–640. DOI:10.1046/j.1468-3083.2003.00691.x PUBMED:https://pubmed.ncbi.nlm.nih.gov/14761128
Silva, MI, et al., & Halbert, GW (2023). Fed intestinal solubility limits and distributions applied to the Developability classification system. European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V 186 74–84. DOI:10.1016/j.ejpb.2023.03.005 PUBMED:https://pubmed.ncbi.nlm.nih.gov/36934829
Gupta, AK, et al., & Tavakkol, A (2005). The use of terbinafine in the treatment of onychomycosis in adults and special populations: a review of the evidence. Journal of drugs in dermatology : JDD 4(3) 302–308. PUBMED:https://pubmed.ncbi.nlm.nih.gov/15898285
Parameters
| Type | Name | Default | Description |
|---|---|---|---|
| Modelica.Units.SI.Mass | weight (from PK_1C) | 75 | patient weight (kg) |
| Modelica.Units.SI.SpecificVolume | VdPerKg (from PK_1C) | 0.9 | Volume of distribution (L/kg) |
| Modelica.Units.SI.MassFraction | F (from PK_1C) | 0.8 | bioavailiability (0-1) |
| Pharmacolibrary.Types.Clearance | Cl (from PK_1C) | 20 | clearance |
| Modelica.Units.SI.Time | adminTime (from PK_1C) | 60 | first administration time (s) |
| Modelica.Units.SI.Time | adminDuration (from PK_1C) | 600 | administration duration (s) |
| Modelica.Units.SI.Time | adminPeriod (from PK_1C) | 8*60*60 | period of administration (default 8 hours)(s) |
| Pharmacolibrary.Types.Mass | adminMass (from PK_1C) | 1000 | administration mass (mg) |
| Integer | adminCount (from PK_1C) | 8 | number of dose administered (1) |
| Pharmacolibrary.Types.Volume | Vd (from PK_1C) | VdPerKg*weight | Volume of distribution (m3) |
| Pharmacolibrary.Types.MassConcentration | Cmin (from PK_1C) | 0.004 | minimal therapeutic range |
| Pharmacolibrary.Types.MassConcentration | Cmax (from PK_1C) | 0.008 | minimal therapeutic range |
| Pharmacolibrary.Types.MassConcentration | Ctox_peak (from PK_1C) | 0.012 | toxicity peak level |
| Pharmacolibrary.Types.MassConcentration | Ctox_trough (from PK_1C) | 0.006 | toxicity trough level |
| Pharmacolibrary.Types.TransferRate | ka (from PK_1C_enteral) | 0.016666666666666666 | first order absorption rate |
| Modelica.Units.SI.Time | Tlag (from PK_1C_enteral) | 600 | delay between oral administration and absorption (default 10min) |
Connectors
| Type | Name | Default | Description |
|---|---|---|---|
| Types.ConcentrationOutput | C_central (from PK_1C) | ||
| Interfaces.ConcentrationPort_b | centralCPort (from PK_1C) |
Components
| Type | Name | Default | Description |
|---|---|---|---|
| Pharmacokinetic.NoPerfusedTissueCompartment | central (from PK_1C) | ||
| Pharmacokinetic.ClearanceDrivenElimination | elim (from PK_1C) | ||
| Sources.PeriodicDose | periodicDose (from PK_1C) | ||
| Modelica.Units.SI.Time | t1_2 (from PK_1C) | elimination half-life |
Revisions
- 06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)